Interventional Neuroradiology Unit, "Federico II" University, Via S.Pansini 5, 80131 Naples, Italy.
Neuroradiology. 2012 Oct;54(10):1145-52. doi: 10.1007/s00234-012-1047-3. Epub 2012 May 9.
We report the experiences of 25 Italian centers, analyzing intra- and periprocedural complications of endovascular treatment of intracranial aneurysms using Silk (Balt Extrusion, Montmorency, France) and pipeline embolization devices (EV3 Inc, Irvine California).
Two hundred seventy-three patients with 295 cerebral aneurysms, enrolled in 25 centers in Italy and treated with the new flow-diverter devices, were evaluated; 142 patients were treated with Silk and 130 with pipeline (in one case, both devices were used). In 14 (5.2 %) cases devices were used with coils. Aneurysm size was >15 mm in 46.9 %, 5-15 mm in 42.2 %, and <5 mm in 10.8 %. Aneurysm locations were supraclinoid internal carotid artery (ICA) in 163 cases (55.2 %), cavernous ICA in 76 (25.7 %), middle cerebral artery in 11 (3.7 %), PCoA in 6 (2 %), and ACoA in 2 (0.7 %); the vertebrobasilar system accounted for 32 cases (10.8 %) and PCA in 5 (1.7 %).
Technical adverse events occurred with 59 patients (21.6 %); 5 patients died after ischemic events, 10 to hemorrhagic complications, and 1 from external ventricular drain positioning. At 1 month, morbidity and mortality rates were 3.7 % and 5.9 %, respectively
Our retrospective study confirms that morbidity and mortality rates in treatment with FDD of unruptured wide-neck or untreatable cerebral aneurysms do not differ from those reported in the largest series.
我们报告了 25 个意大利中心的经验,分析了使用 Silk(Balt Extrusion,Montmorency,法国)和 pipeline 栓塞装置(EV3 Inc,Irvine California)治疗颅内动脉瘤的血管内治疗的围手术期并发症。
在意大利的 25 个中心,共评估了 273 例 295 个颅内动脉瘤患者,这些患者接受了新的血流导向装置治疗;其中 142 例患者接受了 Silk 治疗,130 例患者接受了 pipeline 治疗(1 例患者同时使用了两种装置)。在 14 例(5.2%)患者中,装置与线圈一起使用。动脉瘤大小>15mm 的占 46.9%,5-15mm 的占 42.2%,<5mm 的占 10.8%。动脉瘤位置为颈内动脉(ICA)虹吸部 163 例(55.2%)、海绵窦段 ICA 76 例(25.7%)、大脑中动脉 11 例(3.7%)、后交通动脉 6 例(2%)、前交通动脉 2 例(0.7%);椎基底动脉系统 32 例(10.8%),大脑后动脉 5 例(1.7%)。
59 例患者(21.6%)出现技术不良事件;5 例患者因缺血性事件死亡,10 例患者因出血性并发症死亡,1 例患者因外部脑室引流定位死亡。术后 1 个月,发病率和死亡率分别为 3.7%和 5.9%。
我们的回顾性研究证实,未破裂宽颈或无法治疗的颅内动脉瘤的 FDD 治疗的发病率和死亡率与最大系列报道的无显著差异。